USANA initiated with outperform rating
NEW YORK, September 25 (newratings.com) - Analyst Mark Rupe of Ryan Beck & Co initiates coverage of USANA Health Sciences (USNA.NAS) with an "outperform" rating. The target price is set to $52.
In a research note published this morning, the analyst mentions that the company has posted robust 2Q sales. USANA Health Sciences has the potential to post revenues and EPS growth of 15% and 15-20% annually in the forthcoming several years, the analyst adds. The company has issued robust sales and EPS growth guidance for 2006 of 15%-17% and 17%-20%, respectively.
More USANA news
USANA Q3 Net Sales Fall 4% to $206 Million as Core Customers Slide; Company Trims 2026 Outlook
SALT LAKE CITY, Utah - November 3, 2026 USANA Health Sciences reported third-quarter 2026 net sales of $206 million on November 3, down 4 percent from $214 million a year earlier...
USANA Reports Second Quarter Sales of 223 Million Dollars and Net Loss on Impairment
SALT LAKE CITY, Utah -- August 4, 2026 USANA Health Sciences reported second-quarter 2026 net sales of 223 million dollars, down 5% from 236 million dollars a year earlier. The...
USANA Reports Flat First Quarter Net Sales of 250 Million Dollars
SALT LAKE CITY, Utah -- May 5, 2026 USANA Health Sciences reported fiscal first-quarter 2026 net sales of 250 million dollars, unchanged from the year-earlier quarter, as growth...
USANA Swings to Fourth-Quarter Loss as Active Customers Fall to 387,000
SALT LAKE CITY, Utah -- February 17, 2026 USANA Health Sciences reported fourth-quarter 2025 net sales of 226.2 million dollars, up 6 percent from 213.6 million dollars a year...
USANA Chief Executive Jim Brown Steps Down; Kevin Guest Returns as CEO
SALT LAKE CITY, Utah -- January 8, 2026 USANA Health Sciences said Jim Brown has stepped down as chief executive officer and president and that Kevin Guest, the company's...